Skip to main content
KTTA
NASDAQ Life Sciences

FDA Clears IND for Pasithea's PAS-004 in Cutaneous Neurofibromas, Opening Second Phase 2 Path

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.359
Mkt Cap
$12.297M
52W Low
$0.281
52W High
$2.06
52W Position info
28% above low
Off High info
83% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

KTTA sits 28% above its 52-week low of $0.281.

Summary

The FDA cleared Pasithea's IND for PAS-004 in NF1-associated cutaneous neurofibromas, letting the company run a randomized, placebo-controlled Phase 2 trial in the US. This is the second indication the company is pursuing for its oral macrocyclic MEK inhibitor, alongside the ongoing Phase 1/1b work in plexiform neurofibromas. Management frames the opportunity as a multibillion-dollar market with no FDA-approved systemic therapy for cNF, a condition present in over 95% of NF1 patients; the company estimates more than 80,000 US NF1 patients have moderate-to-severe cNF burden. For a micro-cap clinical-stage biotech, a cleared IND is a real de-risking step but not a data readout — the value hinges on trial start and eventual Phase 2 results. Note the timeline: Nasdaq granted a 180-day extension to February 16, 2027 to regain the $1.00 minimum bid, and stockholders approved a reverse split in September, so the stock remains under listing pressure. The company reported a $50.4 million cash balance in its last 10-Q, which funds the expanded R&D plan for now.

At the time of this announcement, KTTA was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 17, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4343
Real-time Price: $0.4417 info
Change: +$0.0074 (+2%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.4417 info
Change: -$0.0373 (-8%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.4417 info
Change: -$0.0683 (-13%) info
Market Cap: $15.962M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.4417 info
Change: -$0.1083 (-20%) info
Market Cap: $15.962M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.4417 info
Change: -$0.128 (-22%) info
Market Cap: $15.962M info